Marin Biologic Laboratories Releases FDA-Ready Bioanalytical Cell-Based Assays White Paper
New Publication Sets Standard for Phase-Appropriate Assay Qualification, Offering Clear Path from IND to Commercialization
'Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable. This white paper reflects our commitment to excellence.'— Tania Weiss, Ph.D., CEO, Marin Biologic Laboratories
NOVATO, CA, UNITED STATES, June 27, 2025 / EINPresswire.com / -- Marin Biologic Laboratories Inc. (MarinBio), a leading bioanalytical testing and regulatory compliance contract research organization (CRO) based in Northern California, announces the release of a new white paper, 'Selecting Bioanalytical Assays for FDA Approved Clinical Trials and Commercialization.' https://www.marinbio.com/ company/selecting-bioanalytical-assays-fda-clinical-trials-commercialization/
This in-depth publication offers the biopharmaceutical industry a clear, scientifically grounded roadmap for selecting regulatory-ready assays that meet FDA requirements. The white paper walks readers through the full continuum of assay development—from early-stage, fit-for-purpose qualified assays to fully validated, GMP-compliant platforms ready for BLA and NDA submission, and commercialization.
'Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable,' said Tania Weiss, Ph.D., CEO of Marin Biologic Laboratories. 'This white paper reflects our commitment to excellence—scientific, operational, and regulatory—and our desire to enable clients to meet FDA expectations without unnecessary delays or cost overruns. Our goal has always been to act as a true scientific partner to our clients, including those pioneering the next generation of therapeutics. This white paper is a natural extension of that mission. We are codifying three decades of experience to provide the entire industry with a clear, actionable framework for navigating the immense complexities of modern drug development. We believe that sharing our expertise in regulatory strategy and advanced bioanalysis will help accelerate innovation across the board.'
The white paper content leverages MarinBio's 30 years of scientific leadership and impeccable regulatory track record to enable companies on their journey from preclinical projects to commercialization. The publication draws upon MarinBio's deep expertise in GMP/GLP-compliant assay development and its recent successes in passing both FDA, with no 483s, and EU regulatory audits.
Key insights from the white paper include:
- Phase 1: Research-Level Assay Development – Streamlined approaches for initial technology transfer or de novo assay design that deliver reliable, fit-for-purpose data for preclinical and early clinical studies.
- Phase 2: Assay Qualification – Criteria for building a qualified assay for Phase 2 FDA submissions including intermediate precision, accuracy, linearity, and specificity to support IND-enabling studies with confidence.
- Phase 3 & Commercial: GMP Assay Validation – A guideline for validating, and documenting robust assays in full compliance with GLP/GMP and FDA standards—ready for commercial deployment.
The white paper also offers real-world advice for biotech and pharma clients navigating pre-IND/IND readiness and BLA/NDA submissions and commercialization phase —making it an essential read for development teams, regulatory leads, and scientific executives.
About Marin Biologic Laboratories Inc.
Marin Biologic Laboratories (MarinBio) is a woman-owned contract research organization (CRO) with over 30 years of experience supporting the pharmaceutical and biotech sectors. Specializing in custom cell-based assays, GMP/GLP compliance, and regulatory strategy, MarinBio partners with clients to advance therapeutics from discovery to commercialization. With a team of senior PhD scientists and a flawless regulatory audit history, MarinBio provides the scientific expertise and quality systems necessary to meet global compliance standards.
Marin Biologic Laboratories is recognized for its scientific agility, rigorous quality systems, and deep understanding of FDA regulatory expectations. The company is known for working collaboratively with clients, ensuring each assay is customized to meet specific regulatory, technical, and commercial goals.
Operating from a GMP-compliant facility in Novato, CA, MarinBio supports US and international clients ranging from venture-backed startups to top-tier global biopharma firms. The company's service portfolio includes:
- Potency Assays for Lot Release
- Stability Testing
- PK/PD & Immunogenicity Studies (ADA)
- ELISA, Flow Cytometry
- Cell-Based Assays ( https://www.marinbio.com/services/cell-based-assays/ )
- Molecular Biology
- qPCR
- GMP / GLP Compliant Validation and Regulatory Reporting
For the complete white paper or to discuss your bioanalytical assay development needs, please visit the MarinBio website at https://www.marinbio.com/
Tania L. Weiss, Ph.D.
Marin Biologic Laboratories, Inc.
+1 4158838000x100
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Ottawa orders Chinese manufacturer Hikvision to shutter Canadian operations
OTTAWA (Reuters) -The Canadian government has ordered Chinese video surveillance and telecommunications equipment maker Hikvision to cease all operations in the country over national security concerns, Industry Minister Melanie Joly said on Friday. "The government has determined that Hikvision Canada Inc's continued operations in Canada would be injurious to Canada's national security," Joly said on X, adding that the decision was taken after a multi-step review of information provided by Canada's security and intelligence community. Hikvision did not immediately respond to a request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
12 minutes ago
- CNN
Senate barrels toward weekend vote on Trump agenda as GOP support still in limbo
President Donald Trump's push to pass his massive agenda in the Senate is hanging by thread as GOP leaders barrel toward a critical vote this weekend that, as of Friday night, is still short of the support to pass. Just hours after Senate Majority Leader John Thune informed senators they would take a critical first vote on Saturday, a key GOP centrist senator warned he would vote against proceeding to the package unless there are major changes – and several other holdouts are uncertain on how they'll land. That warning shot came from Sen. Thom Tillis, a North Carolina Republican who is up for reelection next November and has been one of the most vocal critics of the Medicaid cuts used to help pay for Trump's tax cuts and spending cuts package. Speaking to reporters Friday, Tillis again raised concerns over the bill's 'fundamentals' and cuts to Medicaid and suggested his vote wouldn't change unless the measure 'transforms radically overnight.' Losing Tillis on Saturday's expected procedural vote – which will be closely watched by Trump – would be a major blow to Senate GOP leaders, who can only afford to lose three Republican votes to advance the bill. Thune and GOP leaders have spent months building to this moment, racing to draft the bill as quickly as possible in an effort to ensure Trump's agenda is on his desk by the Fourth of July. If the bill fails its first procedural vote on Saturday, GOP leaders will have to retool the package, amounting to a huge setback for Trump. And it's not just about that Independence Day timeline: GOP leaders fear that any delay in passing Trump's agenda would embolden the party's critics to seek more changes – which could lead their fragile coalition to fall apart. Already, outspoken fiscal hawk Sen. Rand Paul is planning to vote against it over the plan's inclusion of a $5 trillion debt-limit increase. And Tillis is not the only Republican threatening to oppose the bill over the proposed cuts to Medicaid. Sens. Josh Hawley, Lisa Murkowski, Jerry Moran and Susan Collins have all made similar remarks as they've worked with leadership to trim those provisions. But simply restoring that Medicaid funding may not be enough to win Thune those votes on the floor – it could also cost him votes among Senate GOP hardliners. Sen. Ron Johnson has railed on how the bill is projected to balloon the budget deficit, and another fiscal hawk, Sen. Mike Lee, has suggested he and Johnson along with Sen. Rick Scott could vote as a bloc on Saturday. None have yet to say how they'll vote on the key initial procedural vote Saturday. If all goes to plan, Senate leaders will land the 51 GOP votes to formally begin debating Trump's agenda and then tee up one of the chamber's storied traditions: a series of round-the-clock amendment votes known as vote-a-rama. Democrats will use this overnight session to push on any number of GOP weak points on the bill, particularly Medicaid and other safety net programs. The Senate could then vote on final passage sometime in the middle of the night Saturday or Sunday morning. And if successful, the House would return mid-week to take up the bill with the hope of Trump signing it at the White House on July 4. One of the biggest hurdles for Republicans is the race to rewrite text in compliance with the Senate's complex budget rules, which are governed by the nonpartisan parliamentarian. In recent days, the parliamentarian has ruled against key GOP provisions – from the so-called provider tax, which helps states fund their Medicaid programs to some provisions of a government spectrum auction. That forces the Senate GOP to dial back those provisions, or else Trump's bill would be subject to a Democratic filibuster. Several Republicans said Friday night they need to see the final bill text – which has not been released – before judging whether they would open debate on the sweeping measure. 'I don't have the bill, how can I vote on something I don't know' what's in it, Johnson said. Hawley, who has been deeply concerned about Medicaid cuts, also said the vote hinges on what's in the bill: 'Got to see the text.' Senate GOP leaders hope to release a mostly final version of the bill Friday night or Saturday morning, but the full version may not be ready before the anticipated Saturday vote to open debate, since the Senate Finance Committee is still furiously working to make sure its language complies with the budget rules. The Finance provisions are key because of both tax and health provisions – specifically, Medicaid. 'I still don't have final language from Finance yet, which obviously is of tremendous concern to me given the Medicaid provisions,' Collins said. Multiple GOP senators dismissed concerns about speeding ahead with the vote without final text in hand. 'We discussed this thing ad nauseam,' Ohio Sen. Bernie Moreno said, estimating that Republicans have met on this bill for 'thousands' of hours so far this year. 'The final tax is not out. But we know where we are going.' Sen. Eric Schmitt of Missouri added: 'When you have legislation like this, you're going to have things you need to work through until the very end.' This story has been updated with additional details.
CBS News
15 minutes ago
- CBS News
Berkeley City Council approves zoning change to encourage "middle housing"
In a unanimous vote Thursday night, the Berkeley City Council approved a zoning change designed to make it easier to build small apartment buildings across much of the city—part of a broader effort to address the region's ongoing housing affordability crisis. Dubbed the Middle Housing Ordinance, the new policy streamlines the permitting process for residential buildings such as duplexes, triplexes, and three-story multi-family homes. City officials and housing advocates said the change could increase housing options for middle-income residents who have been increasingly priced out of the market. "These types of units will get a streamlined, 'by-right' approval," said District 1 Councilmember Rashi Kesarwani, who championed the policy. "So if [a project meets] the development standards, they don't go above three stories, and they have setbacks and open space, they can get approved over the counter." The new zoning rules, however, will not apply to the Berkeley Hills, where fire-risk concerns have limited development. Supporters of the ordinance argued that increasing housing supply is essential for reducing costs and giving younger and middle-class residents a foothold in the city's expensive real estate market. "I could not afford one of these houses," said Andrea Horbinski, a renter in the Berkeley Hills with a Ph.D. "And I don't think that is going to change. So hopefully, [developers will] build different housing, new housing, smaller size that I could afford." Horbinski was one of the residents who spoke in favor of the ordinance at the council meeting. "The more the merrier," she said. "The more housing there is, the more prices will come down, the more things will be more affordable for more people." Berkeley's real estate market remains one of the priciest in the region. According to the Bay East Association of Realtors, of the 66 single-family homes sold last month in Berkeley, the median price was $1,812,500. "With what we're projecting, in terms of 50 to 100 homes per year, that's an incremental change," Kesarwani said. "So it'll give us the opportunity to adapt and adjust." Still, not everyone is on board. Some residents fear the zoning change could alter the character of Berkeley's neighborhoods and put added strain on infrastructure. "Why Berkeley, which is already so densely populated and already so hard to get around in?" asked longtime resident Clifford Fred. "It just doesn't make any sense to me." Fred said he's concerned about traffic congestion and limited parking. "Older people who don't have driveways, people need their parking spaces," he said. "I don't think it's selfish for people to have parking spaces near their home." Opponents also criticized the ordinance for not including specific requirements for affordable housing units. But supporters like Horbinski remain hopeful that smaller, lower-cost units will eventually make ownership more attainable. "I think eventually I'll be able to get to a place where I could have a condo or a unit in one of these sort of missing-middle type places," she said. The zoning change is expected to take effect in November. Berkeley follows in the footsteps of Sacramento, which passed a similar measure last year. Santa Rosa is reportedly considering a comparable proposal.
